Literature DB >> 32919110

Fibroblast growth factor 23 concentrations and modifying factors in children from age 12 to 24 months.

Maria Enlund-Cerullo1, Helena Hauta-Alus2, Saara Valkama2, Jenni Rosendahl2, Sture Andersson3, Outi Mäkitie4, Elisa Holmlund-Suila2.   

Abstract

BACKGROUND AND OBJECTIVES: Fibroblast growth factor 23 (FGF23) participates in phosphate, calcium and vitamin D metabolism. In children these interactions and modifying factors are largely unknown. PARTICIPANTS AND METHODS: This study evaluates temporal changes and modifiers of FGF23 concentrations from 12 to 24 months, in healthy children, participating in a randomized vitamin D intervention (VIDI). Participants received vitamin D3 of 10 or 30 μg/day from age 2 weeks to 24 months. At 12 and 24 months, growth measurements and venous blood samples were obtained for analyses of intact (iFGF23) and C-terminal FGF23 (cFGF23), 25-hydroxyvitamin D (25-OHD), calcium, phosphate, parathyroid hormone, iron and ferritin. Changes in FGF23 and modifying factors were examined by linear mixed models.
RESULTS: The study included 594 infants. Girls had higher iFGF23 than boys (p < 0.001 for both 12 and 24 months), cFGF23 did not differ between the sexes. Adjusted mean iFGF23 decreased from 41.4 to 38.1 pg/mL in boys (p < 0.001) and from 45.2 to 42.5 pg/mL in girls (p = 0.002). Adjusted mean cFGF23 decreased from 2.89 to 2.00 pmol/L in boys (p < 0.001) and from 2.92 to 1.93 pmol/L in girls (p < 0.001). Iron modified FGF23 in both sexes, associating positively with iFGF23 and inversely with cFGF23. In girls, 25-OHD modified iFGF23. In boys, season modified FGF23, possibly through seasonal differences in 25-OHD. Vitamin D intervention dose did not affect FGF23.
CONCLUSIONS: FGF23 decreases from 12 to 24 months. Girls have higher iFGF23 than boys, at both time points. Iron modifies FGF23 in both sexes.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical trial; FGF23; Infant; Iron; Vitamin D

Mesh:

Substances:

Year:  2020        PMID: 32919110     DOI: 10.1016/j.bone.2020.115629

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  1 in total

1.  Lipocalin-2 is associated with FGF23 in WNT1 and PLS3 osteoporosis.

Authors:  Petra Loid; Helena Hauta-Alus; Outi Mäkitie; Per Magnusson; Riikka E Mäkitie
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-08       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.